Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
Tóm tắt
• Prior to the commencement of this study, it was already known that rivaroxaban is partially cleared via the kidneys and an influence of renal insufficiency on rivaroxaban pharmacokinetics and exposure was anticipated.
• As many patients in the target indications of rivaroxaban will be elderly, a precise quantitative knowledge of the influence of renal function on rivaroxaban pharmacokinetics and exposure is mandatory for adequate labelling recommendations (in the context of benefit/risk provided by phase III studies) to guide therapy. This study provided detailed insight on both rivaroxaban pharmacokinetics and pharmacodynamic behaviour in renal impairment including severely renally impaired subjects.
This study evaluated the effects of impaired renal function on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban (10 mg single dose), an oral, direct Factor Xa inhibitor.
Subjects (
Renal clearance of rivaroxaban decreased with increasing renal impairment. Thus, plasma concentrations increased and area under the plasma concentration–time curve (AUC) LS‐mean values were 1.44‐fold (90% confidence interval [CI] 1.1, 1.9; mild), 1.52‐fold (90% CI 1.2, 2.0; moderate) and 1.64‐fold (90% CI 1.2, 2.2; severe impairment) higher than in healthy controls. Corresponding values for the LS‐mean of the AUC for prolongation of prothrombin time were 1.33‐fold (90% CI 0.92, 1.92; mild), 2.16‐fold (90% CI 1.51, 3.10 moderate) and 2.44‐fold (90% CI 1.70, 3.49 severe) higher than in healthy subjects, respectively. Likewise, the LS‐mean of the AUC for Factor Xa inhibition in subjects with mild renal impairment was 1.50‐fold (90% CI 1.07, 2.10) higher than in healthy subjects. In subjects with moderate and severe renal impairment, the increase was 1.86‐fold (90% CI 1.34, 2.59) and 2.0‐fold (90% CI 1.44, 2.78) higher than in healthy subjects, respectively.
Rivaroxaban clearance is decreased with increasing renal impairment, leading to increased plasma exposure and pharmacodynamic effects, as expected for a partially renally excreted drug. However, the influence of renal function on rivaroxaban clearance was moderate, even in subjects with severe renal impairment.
Từ khóa
Tài liệu tham khảo
Singer DE, 2008, American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines (8th Edition), Chest, 133, 546S
Bayer Schering Pharma AG.Xarelto® summary of product characteristics. Available athttp://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf(Updated 9 September 2009; last accessed 15 February 2010).
Falga C, 2007, Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry, Thromb Haemost, 98, 771, 10.1160/TH07-02-0132
Sanofi‐aventis.Lovenox (enoxaparin sodium injection) for subcutaneous and intravenous use. Prescribing information. Available athttp://products.sanofi‐aventis.us/lovenox/lovenox.pdf(Updated December 2009; last accessed 24 August 2010).
Glaxo Group Ltd.Arixtra 2.5 mg/0.5 ml solution for injection pre‐filled syringe. Summary of product characteristics. Available athttp://www.medicines.org.uk/emc/medicine/15123(Updated 25 March 2009; last accessed 24 August 2010).